Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar:243:108355.
doi: 10.1016/j.pharmthera.2023.108355. Epub 2023 Feb 3.

How to get rid of itching

Affiliations
Review

How to get rid of itching

Ashley Vander Does et al. Pharmacol Ther. 2023 Mar.

Abstract

Itch is an unpleasant sensation arising from a variety of dermatologic, neuropathic, systemic, and psychogenic etiologies. Various itch pathways are implicated according to the underlying etiology. A variety of pruritogens, or itch mediators, as well as receptors have been identified and provide potential therapeutic targets. Recent research has primarily focused on targeting inflammatory cytokines and Janus kinase signaling, protease-activated receptors, substance P and neurokinin, transient receptor potential-vanilloid ion channels, Mas-related G-protein-coupled receptors (MRGPRX2 and MRGPRX4), the endogenous opioid and cannabinoid balance, and phosphodiesterase 4. Periostin, a newly identified pruritogen, should be further explored with clinical trials. Drugs targeting neural sensitization including the gabergic system and P2X3 are other potential drugs for chronic itch. There is a need for more targeted therapies to improve clinical outcomes and reduce side effects.

Keywords: Atopic dermatitis; Cytokines; Itch; Neuroimmune; Prurigo nodularis; Pruritus.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest G Yosipovitch conducted clinical trials or received honoraria for serving as a member of the Scientific Advisory Board and consultant of Pfizer, TREVI, Regeneron, Sanofi, Galderma, Novartis, Bellus, Kiniksa, and Eli Lilly and received research funds from Pfizer, Leo, Sanofi, Regeneron, Eli Lilly, and Novartis. The remaining authors declare no financial conflict of interest regarding the content of this report.

MeSH terms